Articles tagged "Pharmacokinetics"

2021 American Transplant Congress
Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients
A. Demirag¹, P. L. Lobo², J. Oberholzer¹, A. Kumar², B. Rawashdeh¹, S. L. Lennon¹, H. N. Guvener Demirag¹, A. Doyle², J. Geystone³, K. L. Brayman¹
¹Transplantation, University of Virginia Medical Center, Charlottesville, VA, ²Transplantation Nephrology, University of Virginia Medical Center, Charlottesville, VA, ³Clinical Pharmacy, University of Virginia Medical Center, Charlottesville, VA
*Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…
2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
N. Singh¹, T. Le¹, M. S. Naseer¹, S. Asmil¹, A. Palermini¹, A. Qamar¹, R. Chand¹, S. Tandukar¹, D. Aultman², H. Shokouh-Amiri², G. Zibari²
¹Transplant, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA, ²Advanced Surgery, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…
2021 American Transplant Congress
Elexacaftor/ivacaftor/tezacaftor in Lung Transplant Recipients: A Case Series
L. M. Potter¹, B. Vargas², S. M. Rotolo¹, C. McEwen¹, K. Tsui¹
¹University of Chicago Medicine, Chicago, IL, ²Roosevelt University, Chicago, IL
*Purpose: Little data is published describing the safety or efficacy of elexacaftor/ivacaftor/tezacaftor in lung transplant recipients. Even though it is not expected to offer pulmonary…
2021 American Transplant Congress
The Impact of De Novo Dose-Adjustment Strategies with Tacrolimus XR (LCP-Tac) in Kidney Transplant Recipients
T. Carcella, F. Bartlett, N. Patel, V. Rohan, D. Taber
Medical University of South Carolina, Charleston, SC
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for the prophylaxis of rejection in de novo kidney transplant recipients. It provides less variable…
2021 American Transplant Congress
Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients
J. Hedvat, J. Choe, D. Salerno, J. Scheffert, D. Bley, A. Anamisis, T. Shertel, J. Lee, E. Liu, N. W. Lange
NewYork-Presbyterian Hospital, New York, NY
*Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…
2021 American Transplant Congress
Tacrolimus Therapeutic Exposure is Not Consistently Predicted by Target Troughs or CYP3A5 Variants in Stable Renal Transplant Recipients
K. Tornatore¹, K. Attwood², D. Brazeau³, B. Murray⁴
¹Pharmacy Practice, School of Pharmacy; University at Buffalo, Buffalo, NY, ²Biostatistics, School of Public Health; University at Buffalo, Buffalo, NY, ³Pharmacy Practice, School of Pharmacy; Marshall University, Huntington, WV, ⁴Medicine, Erie County Medical Center Corp., Buffalo, NY
*Purpose: Tacrolimus (TAC) immunosuppression requires therapeutic trough monitoring post-transplant due to notable interpatient pharmacokinetic(PK) variability which may be attributed to CYP3A5 polymorphisms. We investigated the…
2021 American Transplant Congress
Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
M. McGowan¹, A. Bickenbach¹, B. Miyagawa², A. Christianson¹, T. Mizuno², P. West-Thielke³, J. Leone⁴, E. Woodle¹, D. Kaufman⁵, A. Wiseman⁶, A. Matas⁷, A. Vinks², R. Alloway¹
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Children's Med Center, Cincinnati, OH, ³U Illinois, Chicago, IL, ⁴Tampa Gen, Tampa, FL, ⁵U Wisconsin, Madison, OH, ⁶Centura Transplant, Denver, CO, ⁷U Minnesota, Minneapolis, MN
*Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…
2021 American Transplant Congress
Evaluation of Conversion to Extended-Release Tacrolimus in Abdominal Organ and Thoracic Transplant Recipients
A. Diamond¹, N. Agarwal², A. Younas², N. Sifontis², J. Au¹, C. Ruggia-Check¹
¹Pharmacy, Temple University Hospital, Philadelphia, PA, ²Pharmacy, Temple University School of Pharmacy, Philadelphia, PA
*Purpose: An established approach for conversion from immediate-release tacrolimus (IR TAC) to extended-release tacrolimus (LCPT) in kidney transplantation exists, but is lacking in other organ…
2020 American Transplant Congress
Relationship between Tacrolimus Intrapatient Variability and Medication Adherence in Kidney Transplant Recipients
A. D. Leino, K. Abuls, J. L. Rodgers, K. Kuntz
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Intrapatient variability (IPV) has been established as a risk factor for poor post-transplant outcomes. IPV is frequently proposed to be related to nonadherence but…
2020 American Transplant Congress
Basiliximab Induction in the Obese: One Size Does Fit All
A. D. Reticker¹, D. Choi¹, A. B. Lichvar¹, C. Kane², I. Tzvetanov³, E. Benedetti³, J. J. Benken¹
¹Pharmacy Practice, University of Illinois Hospital and Health Sciences System, Chicago, IL, ²Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ³Surgery, University of Illinois Hospital and Health Sciences System, Chicago, IL
*Purpose: Surgical advancements allow more obese (BMI> 30 kg/m2) patients to receive a renal transplant. The original clinical and pharmacokinetic (PK) trials in transplantation immunosuppression…